PETER ROSKAM

Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.

Policies to promote domestic manufacturing.

Financial services policies

Policy issues related to tariffs and domestic manufacturing.

Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.

Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.

Tax provisions that promote domestic manufacturing, including sections of Public Law No. 119-21.

Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.

Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.

Policy issues related to capital markets and the clearance and settlement of securities transactions.

Multiple corporate tax provisions, including those in Public Law No. 119-21 and Public Law No. 115-97.

Policy issues relating to business development companies and the SECs acquired fund fees and expenses rule.

Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.

Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.

Federal regulatory and reimbursement policies relating to medical devices and technologies.

Policy issues related to financial services, accounting and auditing.

Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.

Policies to promote domestic manufacturing.

Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.

Policy issues related to tariffs and domestic manufacturing.

Financial services policies

Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.

Tax provisions that promote domestic manufacturing, including sections of Public Law No. 119-21.

Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.

Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.

Policy issues related to capital markets and the clearance and settlement of securities transactions.

Multiple corporate tax provisions, including those in Public Law No. 119-21 and Public Law No. 115-97.

Policy issues relating to business development companies and the SECs acquired fund fees and expenses rule.

Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.

Federal regulatory and reimbursement policies relating to medical devices and technologies.

Policy issues related to financial services, accounting and auditing.

Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.

Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.

Policies to promote domestic manufacturing.

Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.

Policy issues related to tariffs and domestic manufacturing.

Financial services policies

Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.

Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.

Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.

Tax provisions that promote domestic manufacturing, including sections of Public Law No. 119-21.

Policy issues related to capital markets and the clearance and settlement of securities transactions.

Multiple corporate tax provisions, including those in Public Law No. 119-21 and Public Law No. 115-97.

Policy issues relating to business development companies and the SECs acquired fund fees and expenses rule.

Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.

Federal energy, national security, and research policy related to advanced isotope enrichment technologies and nuclear fuel cycle.

Policy issues related to financial services, accounting and auditing.

Policy issues related to capital markets and the clearance and settlement of securities transactions.

Multiple tax policies, including provisions of Public Law No. 115-97 and Public Law No. 119-21.

Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.

Financial services policies

Federal regulatory and reimbursement policies relating to medical devices and technologies.

Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.

Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.

Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.

Policies to promote domestic manufacturing.

Policy issues related to tariffs and domestic manufacturing.

Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.

Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.

Tax provisions that promote domestic manufacturing, including sections of Public Law No. 119-21.

Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.

Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.

Multiple corporate tax provisions, including those in Public Law No. 119-21 and Public Law No. 115-97.

Policy issues relating to business development companies and the SECs acquired fund fees and expenses rule.

Policy issues related to outsourcing facilities as defined under 503B of Public Law No. 113-54, the Drug Quality and Security Act.

Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.

Federal regulatory and reimbursement policies relating to medical devices and technologies.

Policy issues related to financial services, accounting and auditing.

Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.

Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.

Policy issues related to tariffs and domestic manufacturing.

Policies to promote domestic manufacturing.

Financial services policies

Tax provisions that promote domestic manufacturing, including sections of Public Law No. 119-21.

Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.

Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.

Policy issues related to capital markets and the clearance and settlement of securities transactions.

Multiple corporate tax provisions, including those in Public Law No. 119-21 and Public Law No. 115-97.

Policy issues relating to business development companies and the SECs acquired fund fees and expenses rule.

Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.

Multiple tax policies, including provisions of Public Law No. 115-97 and Public Law No. 119-21.

Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.

Policies regarding the regulation of hearing aids, implants and over-the-counter hearing aid devices, and policies regarding the early identification of and intervention programs for hearing loss.

Policy issues related to financial services, accounting and auditing.

Financial services policy issues relating to digital assets and cryptocurrency.

Federal regulatory and reimbursement policies relating to medical devices and technologies.

Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.

Policy issues related to federal emission regulations for medium- and heavy-duty vehicles.

Policy issues related to tariffs and domestic manufacturing.

Financial services policies

Tax provisions that promote domestic manufacturing, including sections of Public Law No. 117-169.

Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.

Policies that advance market transparency, incentivize capital formation, and ensure a robust secondary market for securities trading, and that would affect national securities exchange liability, immunity and governance.

Policy issues related to capital markets and the clearance and settlement of securities transactions.

Policies to promote domestic manufacturing.

Multiple corporate tax provisions, including those in Public Law No. 115-97, the Tax Cuts and Jobs Act.

Policy issues relating to business development companies and the SECs acquired fund fees and expenses rule.

Telecommunications policy issues, including the commercial wireless spectrum, internet and communications services, broadband availability and infrastructure deployment, cyber security, and privacy.

Multiple tax policies, including provisions of the Tax Cuts and Jobs Act.

Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.

Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.

Financial services policy issues relating to digital assets and cryptocurrency.

Federal regulatory and reimbursement policies relating to medical devices and technologies.

Policy issues related to financial services, accounting and auditing.

Policy issues designed to revitalize the market for small public companies, promote initial public offerings and market transparency, and reduce conflicts of interest in the proxy advisory industry.